Your browser doesn't support javascript.
loading
Mid and long-term overall survival after carcinologic resections of thyroid cancer bone metastases.
Fragnaud, Henri; Mattei, Jean-Camille; Le Nail, Louis-Romée; Nguyen, My-Vân; Schubert, Thomas; Griffin, Anthony; Wunder, Jay; Biau, David; Gouin, François; Bonnevialle, Paul; Vaz, Gualter; Ropars, Mickael; Crenn, Vincent.
Afiliación
  • Fragnaud H; Orthopedics and Trauma Department, University Hospital Hotel-Dieu, CHU Nantes, Nantes, France.
  • Mattei JC; Ramsay Santé, Hôpital Privé Clairval, Marseille, France.
  • Le Nail LR; Département d'Orthopédie, Aix Marseille Université, APHM, Marseille Medical Genetics (MMG), Hôpital NORD, Marseille, France.
  • Nguyen MV; Orthopedics and Trauma Department, University Hospital, of Tours, Tours, France.
  • Schubert T; CNRS ERL 7001 LNOX: Leukemic Niche and Redox Metabolism - EA 7501 GICC (Groupe Innovation et Ciblage Cellulaire), Université de Tours, Tours, France.
  • Griffin A; Orthopedics and Trauma Department, University Hospital Hotel-Dieu, CHU Nantes, Nantes, France.
  • Wunder J; Department of Orthopedic Surgery, Institut de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint Luc, Université Catholique de Louvain (UCLouvain), Brussels, Belgium.
  • Biau D; Division of Orthopaedic Surgery, Musculoskeletal Oncology Unit, Sinai Health System, Toronto, ON, Canada.
  • Gouin F; Division of Orthopaedic Surgery, Musculoskeletal Oncology Unit, Sinai Health System, Toronto, ON, Canada.
  • Bonnevialle P; Orthopedic Department, Cochin Hospital, AP-HP, Paris, France.
  • Vaz G; Surgery Department, Léon Bérard Center, Lyon, France.
  • Ropars M; Orthopedic and traumatology surgery department, Riquet Pierre-Paul Hospital, Toulouse, France.
  • Crenn V; Surgery Department, Léon Bérard Center, Lyon, France.
Front Surg ; 9: 965951, 2022.
Article en En | MEDLINE | ID: mdl-35903257
ABSTRACT

Background:

Bone metastases in thyroid cancer impair the patient's quality of life and prognosis. Interestingly, wide margins resection as the surgical treatment of bone metastases might improve the overall survival (OS). Nonetheless, data are lacking regarding the potential benefits of this strategy.

Methods:

In order to assess the OS of patients with thyroid cancer after a bone metastases carcinologic resection, a retrospective multicentric study was performed, evaluating the 1, 5, 10 and 15 years-OS along with the potential prognosis associated factors.

Results:

40 patients have been included in this multicentric study, with a mean follow-up after surgery of 46.6 ± 58 months. We observed 25 (62.5%) unimestastatic patients and 15 multimetastatic patients (37.5%). The median overall survival after resection was 48 ± 57.3 months. OS at 1, 5, 10, and 15 years was respectively 76.2%, 63.6%, 63.6%, and 31.8%. Survival for patients with a single bone metastasis at 15 year was 82.3%, compared with 0.0% (Log Rank, p = 0.022) for multi-metastatic bone patients.

Conclusions:

This study advocates for an increased long term 10-year OS in patients with thyroid cancer, after resection of a single bone metastasis, suggesting the benefits of this strategy in this population.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Front Surg Año: 2022 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Front Surg Año: 2022 Tipo del documento: Article País de afiliación: Francia